Fig. 3From: Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case reportComparison of diagnostic criteria for “CML-AP” in the 2017 WHO (left row) [17], “high risk CP-CML” according to 5th WHO edition (middle row) [19], and simplified “AP-CML” in the 2022 ICC (right row) [20]. AP = accelerated phase; CP = chronic phase; ELTS = The EUTOS long-term survival score; ACA = additional cytogenetic abnormalities; TKI = tyrosine kinase inhibitorBack to article page